Smart Dialysis Ecosystems: Next Generation Precision Care Using AI
Today, the country has barely 50,000 dialysis machines to serve a population that requires more than double that number. Almost 60% of patients are forced to travel more than 50 km per session, resulting in dropouts, delayed treatment, and potentially avoidable complications.
What India needs is not only a greater number of such centers, but also smarter and interconnected dialysis ecosystems enhanced by the power of artificial intelligence, machine learning, and IoT. These new-age technologies are establishing the foundation of
precision care in nephrology
.
The Artificial Intelligence Revolution in Kidney Care
Predictive analytics is the driving force of this evolution. Artificial intelligence models can currently process real-time data on blood pressure trends, fluid levels, and treatment history to predict complications like intradialytic hypotension with more than 90% accuracy. Such proactive monitoring reduces the need for emergency interventions and enhances patient safety on a larger scale.
What's more, personalized treatment plans, once an elite hospital's privilege, are becoming scalable. Adjusting the duration of dialysis, rates of fluid removal, and doses of medication according to individual patient profiles gives rise to the concept of machine learning. This results in significantly better outcomes, 20 to 30% better, and allows patients to lead more complete lives despite living with a chronic disease.
Reducing the Urban-Rural Divide With Remote Monitoring
The fact on the ground is plain: most dialysis centres are based in the cities. But now, with monitoring-capable dialysis machines and the Internet of Things, nephrologists can remotely monitor sessions at rural and semi-urban centres. This both enhances quality control and saves on patient travel time and dropout rates.
Operationally, Artificial Intelligence is increasing efficiency as well, through automated scheduling, inventory management, and predictive maintenance for machines. These advancements result in reduced costs, decreased absence of usage sessions, and greater dependability—all key factors in a resource-limited healthcare environment.
Creating an Ecosystem: Policy, Partnerships and Purpose
It's crucial that dialysis care doesn't progress in isolated silos. Public-private partnerships (PPPs) like the ones envisioned by the Pradhan Mantri National Dialysis Program are essential for scaling up smart dialysis solutions. The Indian government has emphasized indigenous manufacturing and digital health, paving the way for Artificial Intelligence to become a mainstream part of healthcare delivery.
Sustainability is another key benefit. Smart dialysis centres are more conservative about water and power use, and they are less wasteful in their approach. Predictive tools help prevent machine downtime, making it viable even in the most remote or under-resourced parts of the country.
A Glimpse into the Future
Artificial Intelligence is not the end; it's the beginning and the enabler behind achieving quality dialysis equity for all. As we now move into the age of 3D-printed organs, AI-augmented artificial kidneys, and real-time biomarker monitoring, our vision at NephroPlus extends beyond treatment.
Our zero-cost Hepatitis C elimination program across Bihar and Andhra Pradesh has screened and treated hundreds of dialysis patients, showcasing the power of data-driven, integrated, and patient-first care.
On top of that, NephroPlus uses data-driven insights to enhance patient care by spotting trends and refining treatment plans. This enables us to tailor our services to meet each patient's unique needs more effectively.
India is well-positioned to become the global leader in smart dialysis care, not by emulating the Western model but by creating smart, scalable, and sustainable systems that fit our ground realities.
This article is written by Vikram Vuppala Founder and CEO, NephroPlus
Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Centre approves 100-bed yoga and naturopathy hospital in Guntur
The Central government has approved the establishment of a 100-bed hospital under the Central Research Institute of Yoga and Naturopathy (CRIYN) at Nadimpalem village in Prathipadu mandal of Guntur district, with a total outlay of ₹94 crore. Union Minister of State for Rural Development and Communications, Dr. Pemmasani Chandra Sekhar, on Thursday informed that the hospital will be built on 15 acres under the Ministry of AYUSH and will be fully funded by the Centre. The hospital will include modern medical facilities, a scientific research centre, a training institute, and residential quarters for medical staff. The project aims to offer round-the-clock integrated healthcare services, blending traditional Indian medicine with scientific research. Minister Pemmasani said the centre would serve as a national hub for research, training, and treatment in yoga and naturopathy, contributing to healthier lifestyles through traditional practices. He termed it as a major opportunity not just for Guntur but for entire Andhra Pradesh. He expressed gratitude to Prime Minister Narendra Modi, Union Minister of State (Independent Charge) of the Ministry of Ayush Jadhav Prataprao Ganpatrao, and the Central government, highlighting that the project is a milestone in Andhra Pradesh's healthcare development under Chief Minister N. Chandrababu Naidu's leadership.
NDTV
3 hours ago
- NDTV
Covid Vaccines Not Behind Sudden Deaths, Suggests Top Medical Body Study
New Delhi: None of the Covid vaccine doses are linked to heart attacks and deaths, said Dr Sudheer Arava from AIIMS, who is part of the research currently underway by the Indian Council of Medical Research (ICMR) and the All India Institute of Medical Sciences (AIIMS). Speaking to IANS, he noted that preliminary data so far has shown no indication between heart attack and Covid jabs, developed in the country. "Till now, our study data says that the vaccine has no effect on the cause of death, whether it is a first dose, second dose or third dose, there is no difference in it," Arava added. His comments amid concerns over several heart attack deaths being seen in the country. About the study, Arava, from AIIMS' Department of Pathology, said that it was launched by the ICMR, in the aftermath of deaths happening in the country after the arrival of Covid. Initial results, soon to be published, indicate that 50 per cent of the deaths caused among individuals between 18 to 45 years are due to heart attacks. The other finding is "unexplained death, in which we could not ascertain the cause". Further, to understand whether the deaths match with those during pre-COVID days, they analysed previous data but found no difference in the cause of death. "We found out that the pattern of death rate among young individuals in pre-COVID times is similar to that of during COVID. We did not find any effect of the vaccine in this... There is no clear-cut indication saying that the vaccine causes sudden death in young individuals," Arava told IANS. "The benefits of vaccines far outweigh the very small possible side effects," added Dr Rajiv Narang from the Department of Cardiology, AIIMS. He added that "people should be aware that a heart attack is not a simple issue -- there can be many causes for sudden cardiac arrest". Meanwhile, the Indian Vaccine Manufacturers Association (IVMA) also issued a statement assuring the safety of the Covid vaccines developed in the country. "Covid-19 vaccines of India were developed and manufactured with the highest safety and quality standards," IVMA Director General, Dr G.V.J.A. Harshavardhan, said. "All Covid-19 vaccines in India were approved for Emergency Use Authorisation (restricted use in emergency situations of the WHO guidelines)," he added. Harshavardhan noted that the approvals were based on extensive evaluation in preclinical studies and human clinical trials. He stated that the Indian vaccines not only helped "control the Covid-19 pandemic and restrict its impact on lives, livelihoods, but most importantly, enabling India's economic activity and GDP to rebound and grow to new heights globally". Harshavardhan said that the benefits of India-made Covid jabs were also extended to several countries worldwide, under the government's Vaccine Maitri programme. "We hereby reassure the public on the safety and efficacy of Covid-19 vaccines," he said.
Time of India
5 hours ago
- Time of India
Govt Reaffirms COVID Vaccine Safety as Private Hospitals Stay Quiet—Raising Questions
New Delhi: As concerns about sudden cardiac deaths among young adults continue to make headlines, the Indian government and top pharmaceutical voices have reiterated that COVID-19 vaccines are safe, effective, and not linked to heart-related fatalities. However, a curious silence from leading private hospitals and senior doctors—who played a central role in the nationwide vaccination drive—is beginning to raise questions about transparency and public engagement. Private hospitals, which were deeply involved in the vaccination rollout, remaining silent at this juncture cannot be taken lightly. This silence is not necessarily an admission of doubt, but the absence of their voice in the public domain—especially when scientific clarity is most needed—has not gone unnoticed. Health authorities maintain that India's vaccines have undergone rigorous testing and regulatory scrutiny. Dr. G.V.J.A. Harshavardhan, Director General of the Indian Vaccine Manufacturers Association, in an official statement, reaffirmed:'COVID-19 vaccines of India were developed and manufactured with the highest safety and quality standards. Patient safety and product quality are always prioritized during the vaccine development and its manufacture.' He added that all vaccines were approved for Emergency Use Authorization (EUA) based on extensive preclinical and clinical trials demonstrating safety, efficacy, and immunogenicity. 'Prior to their release, all COVID-19 vaccines are tested extensively for safety by the manufacturers and are also provided Batch Release Certification by the Central Drugs Laboratory (CDL), Kasauli, Himachal Pradesh, of the Ministry of Health and Family Welfare,' he said. 'The strengths of innovation and large-scale high-quality manufacturing are the hallmarks of the Indian vaccine ecosystem.' India's Global Vaccine Leadership During the pandemic, India supplied vaccines to over 90 countries under its Vaccine Maitri initiative. Officials cite this as proof of international confidence in Indian-made vaccines. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, echoed this sentiment and raised concerns about the harmful impact of misinformation. 'The Indian pharmaceutical industry is a knowledge-driven sector and plays a vital role in global health. India accounts for 60 per cent of global vaccine production. These vaccines have been well documented and rigorously tested as per regulatory processes,' he said. 'Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally.' Private Hospitals, Key Vaccination Partners, Maintain Silence as Questions Mount Despite these strong assurances, prominent private hospitals and top medical experts associated with them have largely refrained from commenting on the rising concerns related to post-vaccination adverse events . ETHealthworld reached out to several hospital networks involved in mass immunization, but most declined to comment or said they had no official position at this time. This silence is puzzling. These institutions were once highly vocal during the vaccine rollout, actively conducting drives, issuing FAQs, and promoting vaccine awareness. Their muted response today, amid public anxiety, is being seen as a missed opportunity to educate and reassure. 'We're not blaming hospitals,' said a senior public health expert, 'but their absence in this conversation is noticeable. If the data supports vaccine safety—as government and pharma leaders insist—then trusted medical institutions should lead from the front, explaining how adverse events are monitored and managed. Silence only deepens doubt.' Experts say the role of private hospitals is critical not just in vaccine delivery, but in reinforcing public trust. With vaccine hesitancy rising globally, communication gaps—especially from frontline players—risk allowing misinformation to fill the void. Why Transparency Now Matters More Than Ever? In an age where misinformation travels faster than facts, silence can be dangerous. Transparency—even when dealing with rare or uncomfortable adverse events—is essential to preserving long-term confidence in scientific interventions. India's COVID-19 vaccination program has been widely praised for its scale and speed. But success in public health doesn't end with delivery—it continues through open dialogue, education, and the courage to confront evolving narratives head-on. As the debate around vaccine safety intensifies, it is essential that all stakeholders—government bodies, pharmaceutical leaders, and healthcare institutions—participate in a unified, fact-based public conversation. Rebuilding and reinforcing public trust isn't just a policy goal. It's a shared responsibility.
